The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Lysosomal Biomarkers Program, 2023Developing a Targeted Proteomic Test to Monitor Blood Samples for Lysosomal Signatures of Parkinson’s Disease
Study Rationale: Lysosomes are structures that help clear cells of molecular debris, and lysosomal dysfunction has been linked to neurodegeneration in Parkinson’s disease (PD). In this study, we will...
-
Lysosomal Biomarkers Program, 2023Measurement of Neuronal Extracellular Vesicles as a Blood-based Biomarker for Lysosomal Function
Study Rationale: Parkinson’s disease (PD) is associated with the aggregation of toxic proteins, a buildup due partly to the reduced ability of lysosomes to degrade these proteins. Improving lysosome...
-
Research Grant, 2023(SUPPLEMENT) Development of an Imaging Tracer for Measuring Alpha-synuclein
Study Rationale: The discovery of new treatments for Parkinson’s disease (PD) has been hampered by the amount of time it can take (typically a number of years) to determine whether a drug works in a...
-
Research Grant, 2023Development of a Protein Biomarker Panel to Measure Parkinson’s Disease Heterogeneity and Progression
Study Rationale: According to The Michael J. Fox Foundation, the need for biomarkers that provide an objective assessment for Parkinson’s disease (PD) “has become more urgent as more projects enter...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Interrogating LRRK2 Variants Common in Asian Populations to Discover Unique Biomarkers for Parkinson’s Disease
Study Rationale: Mutations in the LRRK2 gene are the most common genetic cause of Parkinson's disease (PD). Many studies have focused on the LRRK2 G2019S mutation found in Caucasians, and less is...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2023Development of Parkin Activators for the Treatment of Parkinson’s Disease
Study Rationale: Impaired function of cell structures called mitochondria plays a key role in the pathology of Parkinson’s disease (PD): alpha-synuclein accumulation damages mitochondria, dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.